Takeda Pharmaceutical Co Ltd
4502: XTKS (JPN)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
¥8,264.00 | Hsh | Mtsrsvxf |
Takeda’s Fiscal Q2 Earnings in Line; FVE Unchanged, Shares Fairly Valued
Narrow-moat Takeda’s second fiscal quarter was in line with our expectations after adjusting for currency tailwinds due to the depreciating yen. Revenue was JPY 1,002 billion, which is 18.6% year-on-year growth and 2.8% growth after adjusting for currency. Core operating profit was JPY 306.1 billion, representing 30.5% core operating profit margin, which is also in line with our forecast.